Pfizer (PFE) Tops Q3 EPS by 34, Beats on Revenue; Offers FY Guidance

Pfizer (NYSE: PFE) reported Q3 EPS of $1.78, $0.34 better than the analyst estimate of $1.44. Revenue for the quarter came in at $22.6 billion versus the consensus estimate of $21.33 billion.

GUIDANCE:

Pfizer sees FY2022 EPS of $6.30-$6.45, versus the consensus of $6.38. Pfizer sees FY2022 revenue of $99.5-102 billion, versus the consensus of $99.6 billion.

The company raises 2022 Revenue Guidance for Comirnaty(1) by $2 Billion to ~$34 Billion and Reaffirms Revenue Guidance for Paxlovid of ~$22 Billion, Despite Unfavorable Impacts from Foreign Exchange.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Pfizer (PFE) Reiterated at Neutral by Cantor Fitzgerald on Negative SV Data